First-In-Human Dose-Escalation Study of Fianlimab, an Anti-Lymphocyte Activation Gene-3 Antibody, with Cemiplimab in patients with advanced malignancies.
Lakhani NJ, Papadopoulos KP, Johnson ML, Park H, Wang D, Yap TA, Dowlati A, Maki RG, Ulahannan S, Lynce F, Kelly K, Williamson S, Malhotra J, Chen S, Gonzalez Ortiz A, Jankovic V, Paccaly A, Masinde S, Mani J, Lowy I, Gullo G, Sims T, Kroog G.
Lakhani NJ, et al. Among authors: wang d.
Clin Cancer Res. 2024 Oct 18. doi: 10.1158/1078-0432.CCR-23-3883. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 39422598